Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer: A case report and review of literature

Table 1 Summary of evidence for main gene mutations

Genes mutation	Ref.	Total No. of patients	Frequency		Prognosis
			n	%	OS	RFS
KRAS1	Nash et al[19], 2010	188	51	27	Worse
	Teng et al[24], 2012	292	111	38	None
	Karagkounis et al[20], 2013	202	58	29	Worse	Worse
	Lin et al[21], 2014	154	43	28	None
	Margonis et al[22], 2016	512	190	37		None
	Wang et al[23], 2017	300	110	37	Worse
TP53	Tullo et al[25], 1999	40	19	48		Worse
	Yang et al[27], 2001	39	16	41	Better	Better
	Saw et al[26], 2002	60	35	58	None
	De Jong et al[30], 2005	44	16	36	None	None
	Molleví et al[28], 2007	91	46	51	Worse
	Pilat et al[29], 2015	76	42	55	Worse
	Løes et al[33], 2016	164	99	60	None	None
	Frankel et al[31], 2017	165	95	58	None
	Chun et al[32], 2019	401	263	66	None
SMAD4	Mizuno et al[35], 2018	278	37	13	Worse
	Kawaguchi et al[36], 2019	507	56	11	Worse	Worse
APC2	Yamashita et al[34], 2020	396	45	11	Worse	Worse

¹More than 150.

²Represent APC and PIK3CA mutation. OS: Overall survival; RFS: Recurrence-free survival.